Overview

A Randomized Study of AZD2014 in Combination With Fulvestrant in Metastatic or Advanced Breast Cancer

Status:
Active, not recruiting

Trial end date:
2020-07-31

Target enrollment:

Participant gender:

Summary

This is an open-label, multicentre, 4-arm randomised phase II trial of fulvestrant + AZD2014 versus fulvestrant + everolimus versus fulvestrant alone in patients with ER-positive, HER2-negative advanced or metastatic breast cancer, whose disease relapsed during treatment with (or within 12 months after discontinuation of) an AI in the adjuvant setting or progressed during treatment with an AI in the metastatic setting. Patients will be randomised (2:3:3:2) to one of the four treatment arms: - Fulvestrant - Fulvestrant + AZD2014 (continuous daily schedule) - Fulvestrant + AZD2014 (intermittent schedule - 2 days on, 5 days off) - Fulvestrant + everolimus Randomization will be stratified by the following criteria: - Measurable disease (vs. non-measurable). - Sensitivity to prior endocrine therapy (sensitive versus resistant)

Phase:

Phase 2

Details

Lead Sponsor:

Queen Mary University of London

Collaborator:

AstraZeneca

Treatments:

Estradiol
Everolimus
Fulvestrant
Sirolimus